1138 GMT - European defense and pharmaceutical stocks are expected to perform strongly beyond 2025, Moody's analysts Martin Kohlhase and Marina Albo say in a note to investors. Europe's defense companies continue to benefit from structural demand drivers that are unlikely to abate in the next years, they say. Their order books are strong and cover between two and five years of revenue, they write. Global supply-chain challenges affecting aerospace and defense companies pose the main risk to Moody's double-digit percentage operating profit growth forecast for 2025, they note. Meanwhile, demand for weight-loss and diabetes drugs as well as the strong growth of oncology and immunology treatments should keep pharmaceutical stocks high, the analysts say. (cristina.gallardo@wsj.com)
(END) Dow Jones Newswires
November 20, 2024 06:40 ET (11:40 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。